Regeneron Pharmaceuticals (REGN) reported $14.3B in revenue for fiscal 2025, +1.0% year on year. That ranks #386 by revenue among 2853 SEC filers and #40 in Healthcare. Net income was $4.5B, a net margin of 31.4%. Revenue has grown 28.1% a year on average since 2011 ($446M then). The fiscal 2025 balance sheet shows $40.6B in total assets, $3.1B in cash and $2.0B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $14.3B | +1.0% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $3.6B | −10.3% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $4.5B | +2.1% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $5.0B | +12.6% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $898M | +18.9% | FY20252025-12-31 |
| Total assetsAssets | $40.6B | +7.4% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $31.3B | +6.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $3.1B | +25.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $2.0B | +0.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $3.6B | $727M | Open → |
| Q2 20262026-06-30 | $4.3B | $1.3B | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 10 of 161 companies compared | 31.4% | |
| Operating marginRank 23 of 160 companies compared | 24.9% | |
| R&D as share of revenueRank 6 of 102 companies compared | 40.8% | |
| Cash as share of revenueRank 45 of 160 companies compared | 21.7% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Regeneron Pharmaceuticals, Inc.
- Ticker
- REGN
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000872589
Filings
- 10-QJul 30, 2026Open filing →
- 10-QApr 29, 2026Open filing →
- 10-KFeb 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| AflacAFL | $17.2B | $3.6B |
| IQVIA HoldingsIQV | $16.3B | $1.4B |
| Principal FinancialPFG | $15.6B | $1.3B |
| Regeneron PharmaceuticalsREGN | $14.3B | $4.5B |
| ViatrisVTRS | $14.3B | −$3.5B |
| Labcorp HoldingsLH | $14.0B | $877M |
| DavitaDVA | $13.6B | $1.1B |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Regeneron Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/regeneron-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Regeneron Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/regeneron-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-regeneron-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Regeneron Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/regeneron-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000872589-26-000008 · February 4, 2026
{{cite web |title=Regeneron Pharmaceuticals — Key figures — 10-K (0000872589-26-000008) |url=https://www.sec.gov/Archives/edgar/data/872589/000087258926000008/regn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-04}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.